Merdad V. Parsey

Chief Medical Officer at Gilead Sciences, Inc.

Merdad V. Parsey

Merdad V. Parsey

Chief Medical Officer at Gilead Sciences, Inc.

Overview
Career Highlights

3-V Biosciences, Inc.

RelSci Relationships

4650

Number of Boards

1

Contact Data
Trying to get in touch with Merdad V. Parsey? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Merdad V. Parsey likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at 3-V Biosciences, Inc.

Relationship likelihood: Strong

General Partner, Washington DC at New Enterprise Associates

Relationship likelihood: Strong

Director at Zyngenia, Inc.

Relationship likelihood: Strong

Managing Director at Westlake Village BioPartners

Relationship likelihood: Strong

President & Chief Financial Officer at Kite Pharma, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Gilead Sciences, Inc.

Relationship likelihood: Strong

Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer at Gilead Sciences, Inc.

Relationship likelihood: Strong

Principal, Washington DC at New Enterprise Associates

Relationship likelihood: Strong

Co-Founder at TESARO, Inc.

Relationship likelihood: Strong

Former President-Research & Development at MedImmune LLC

Relationship likelihood: Strong

Paths to Merdad V. Parsey
Potential Connections via
Relationship Science
You
Merdad V. Parsey
Chief Medical Officer at Gilead Sciences, Inc.
Education
Unknown

The University of Maryland, College Park is a public research university, the flagship campus of the University System of Maryland, and the original 1862 land-grant institution in the State. The University of Maryland is committed to achieving excellence as the State’s primary center of research and graduate education and the institution of choice for undergraduate students of exceptional ability and promise. The University creates and applies knowledge for the benefit of the economy and culture of the State, the region, the nation, and beyond. As the flagship of the University System of Maryland, the University shares its research, educational, cultural, and technological strengths with businesses, government, and other educational institutions. The University counts among its greatest strengths -- and a major component of its excellence -- the diversity of its faculty, students, and staff. The University of Maryland, College Park is committed to equal educational opportunity and strives to hire a diverse faculty and staff of exceptional achievement through affirmative actions, to celebrate diversity in all of its programs and activities, and to recruit and retain qualified graduate and undergraduate minority students.

Career History
Chief Medical Officer
2019 - Current

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Senior Director-Medical Group
Current

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases and opportunistic areas. The company was founded by Herb W. Boyer, Kenneth B. Lee and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

President, Chief Executive Officer & Director
2010 - 2015

3-V Biosciences, Inc. discovers and develops novel therapeutics for the treatment of infectious diseases. It evaluates TVB-2640 as monotherapy and in combination with paclitaxel in a Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast cancer and ovarian cancer. The company was founded in 2006 and is headquartered in Menlo Park, CA.

Transactions
Details Hidden

3-V Biosciences, Inc. raised money in a private placement transaction

Details Hidden

3-V Biosciences, Inc. raised money in a private placement transaction

Details Hidden

3-V Biosciences, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Merdad V. Parsey. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Merdad V. Parsey's profile does not indicate a business or promotional relationship of any kind between RelSci and Merdad V. Parsey.